Literature DB >> 20801771

Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response.

D Turner1, S T Leach, D Mack, K Uusoue, R McLernon, J Hyams, N Leleiko, T D Walters, W Crandall, J Markowitz, A R Otley, A M Griffiths, A S Day.   

Abstract

OBJECTIVE: To compare four faecal markers for their ability to predict steroid refractoriness in severe paediatric ulcerative colitis (UC). Construct validity and responsiveness to change were also assessed.
METHODS: This was a prospective multicentre cohort study. Stool samples from 101 children (13.3 + or - 3.6 years; Pediatric UC Activity Index (PUCAI) at admission 72 + or - 12 points) were obtained at the third day of intravenous steroid therapy. Repeated samples at discharge were obtained from 24 children. Predictive validity was assessed using diagnostic utility statistics to predict steroid failure (ie, the need for salvage treatment). Concurrent validity was assessed using correlational analysis with the following constructs: PUCAI, Lindgren and Seo scores, physician's global assessment, albumin, erythrocyte sedimentation rate and C-reactive protein (CRP). Responsiveness was assessed using test utility and correlational strategies.
RESULTS: Median values (IQR) were very high at baseline for all four markers (calprotectin 4215 microg/g (2297-8808); lactoferrin 212 microg/g (114-328); M2-pyruvate kinase (M2-PK) 363 U/g (119-3104); and S100A12 469 microg/g (193-1112)). M2-PK was numerically superior to the other three markers and CRP in predicting response to corticosteroid treatment (area under the receiver operating characteristic (ROC) curve 0.75 (95% CI 0.64 to 0.85; p<0.001) vs <0.65 for the others). However, it did not add to the predictive ability of the PUCAI (area under the ROC 0.81 (95% CI 0.73 to 0.89)). M2-PK also had the highest construct validity but with a modest mean correlation with all constructs (r=0.3; p<0.05). None of the markers was responsive to change (Spearman's rho correlation with change in the PUCAI <0.1; p>0.05, area under the ROC curve <0.65; p>0.05).
CONCLUSIONS: The four markers were greatly elevated in severe paediatric UC. Only M2-PK had good construct and predictive validity, and none was responsive to change. The PUCAI, a simple clinical index, performed better than the faecal markers in predicting outcome following a course of intravenous corticosteroids in severe UC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20801771     DOI: 10.1136/gut.2010.211755

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  33 in total

1.  Predictors of aggressive inflammatory bowel disease.

Authors:  Andres J Yarur; Sebastian G Strobel; Amar R Deshpande; Maria T Abreu
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-10

2.  Fecal M2-PK in children with Crohn's disease: a preliminary report.

Authors:  A S Day; T Judd; D A Lemberg; S T Leach
Journal:  Dig Dis Sci       Date:  2012-06-27       Impact factor: 3.199

Review 3.  The role and utility of faecal markers in inflammatory bowel disease.

Authors:  Frank S Lehmann; Emanuel Burri; Christoph Beglinger
Journal:  Therap Adv Gastroenterol       Date:  2015-01       Impact factor: 4.409

4.  Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy.

Authors:  Marcello Cintolo; Giuseppe Costantino; Socrate Pallio; Walter Fries
Journal:  World J Gastrointest Pathophysiol       Date:  2016-02-15

5.  Contribution of susceptibility variants at FCGR2A and 13q12 to the risk of relapse among Japanese patients with ulcerative colitis.

Authors:  Kouichi Asano; Motohiro Esaki; Junji Umeno; Atsushi Hirano; Yuji Maehata; Tomohiko Moriyama; Shotaro Nakamura; Takayuki Matsumoto; Takanari Kitazono
Journal:  J Gastroenterol       Date:  2015-03-19       Impact factor: 7.527

Review 6.  Biomarkers as potential treatment targets in inflammatory bowel disease: A systematic review.

Authors:  Travis Murdoch; Sarah O'Donnell; Mark S Silverberg; Remo Panaccione
Journal:  Can J Gastroenterol Hepatol       Date:  2015-05

7.  Proteomic patterns of colonic mucosal tissues delineate Crohn's colitis and ulcerative colitis.

Authors:  Erin H Seeley; Mary K Washington; Richard M Caprioli; Amosy E M'Koma
Journal:  Proteomics Clin Appl       Date:  2013-05-08       Impact factor: 3.494

Review 8.  Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome.

Authors:  Jan Däbritz; Jason Musci; Dirk Foell
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

Review 9.  Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.

Authors:  Jason Orlando Dimitri Musci; Jack Stephen Cornish; Jan Däbritz
Journal:  J Gastroenterol       Date:  2016-03-14       Impact factor: 7.527

10.  Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis.

Authors:  Carolin Tonus; Markus Sellinger; Konrad Koss; Gero Neupert
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.